Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision changed from v3.2.0 to v3.3.2 with no visible changes to the Study Details page, its content, or study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page removed a generic federal operating status notice. This change does not affect the study details or how to participate.SummaryDifference0.3%

- Check41 days agoChange DetectedThe screenshots show only minor formatting and timestamp updates, with no changes to eligibility criteria, study design, endpoints, or recruitment locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedCore content updated to inform users about funding-related operating status and current NIH Clinical Center openness; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

- Check69 days agoChange DetectedPage now shows Revision: v3.1.0 and adds a batch of contact details (phone numbers and emails) for various individuals. Deletion indicates removal of v3.0.2.SummaryDifference0.1%

- Check84 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed, with no substantive content changes otherwise.SummaryDifference0.2%

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.